Key result
ACTH 1-24 infusion decreased baroreflex sensitivity from ~18 mmHg/ms to 15 mmHg/ms in healthy subjects, implicating the hypothalamic-pituitary-adrenal axis in hypoglycemia-associated autonomic failure.
Why the study?
Does ACTH infusion decrease baroreflex sensitivity in healthy subjects?
Does ACTH infusion decrease baroreflex sensitivity in healthy subjects?
Answers are grounded in this paper and cite their sources.
ACTH infusion decreases baroreflex sensitivity, suggesting the hypothalamic-pituitary-adrenal axis plays a role in the baroreflex impairment seen in hypoglycemia-associated autonomic failure.
A single bout of hypoglycemia impairs the counterregulatory symptomatic, autonomic, and neuroendocrine (eg, glucagon, epinephrine, norepinephrine, ACTH, cortisol, pancreatic polypeptide, growth hormone) responses to a subsequent episode of hypoglycemia. Recurrent hypoglycemia blunts those responses and induces a state of hypoglycemia-associated autonomic failure (HAAF), characterized by defective glucose counterregulation and hypoglycemia unawareness (1,2). Patients with HAAF are at a markedly increased risk of suffering potentially fatal episodes of severe hypoglycemia. Besides the metabolic and hormonal defects, impairment of baroreflex sensitivity and blunting of muscle sympathetic nerve activity also occur following recent antecedent hypoglycemia, and both features are components of the HAAF syndrome (3). Although recent antecedent hypoglycemia was the known trigger in its initial description, prior exercise and sleep are now recognized to also induce HAAF, which might explain the increased vulnerability to hypoglycemia postexercise and during nocturnal hours (2). Currently, there is no unifying explanation for the myriad manifestations of HAAF. Some proposed mechanisms include systemic mediator(s) released during hypoglycemia, activation of central (thalamic) inhibitory or excitotoxicity pathways, and altered gene expression in GABAergic neurons, among others (1,4). The systemic mediator hypothesis posits that a humoral factor triggered by hypoglycemia signals central regulatory sites to suppress neuroendocrine and symptomatic responses to subsequent hypoglycemia (4). Cortisol and epinephrine have been proposed as candidates, but studies have been conflicting. Neither experimental elevation of plasma cortisol nor inhibition of cortisol biosynthesis using metyrapone significantly altered sympathoadrenal or symptomatic responses to subsequent hypoglycemia in humans (4). Assuming that central corticotropin-releasing hormone (CRH) levels also increased during metyrapone treatment (and spilled over into systemic circulation), the latter observations would seem to also eliminate CRH as a likely mediator of the metabolic and hormonal components of HAAF. As previously noted, impaired baroreflex sensitivity is a recognized component of HAAF. Fluctuations in blood pressure are sensed by baroreceptors in the carotid sinus and aortic arch, which reflexly regulate heart rate and peripheral vascular tone to restore hemodynamic homeostasis. Antecedent hypoglycemia blunts the compensatory physiological baroreflex responses to changes in blood pressure, and impaired baroreflex sensitivity is associated with adverse cardiac events, including death (5). In this issue of the Journal of Clinical Endocrinology & Metabolism, Leung and colleagues explored the role of the hypothalamic-pituitary-adrenal axis in the regulation of baroreflex sensitivity. Using a randomized, placebo-controlled, double-blind, cross-over study design, the investigators tested the effect of ACTH 1–24 (cosyntropin) infusion for 2.5 h in the morning and again in the afternoon on baroreflex sensitivity in healthy subjects. Their hypothesis was that ACTH infusion would decrease baroreflex sensitivity in a manner that mimics the effect of antecedent hypoglycemia (acute suppression, with prolonged effect). The authors report that ACTH infusion significantly decreased baroreflex sensitivity during the final 30 min of the morning infusion, an effect that lasted for 16 h after the afternoon infusion. The inference from these findings is that increased ACTH levels during hypoglycemia could explain the hypoglycemia-associated impairment of baroreflex sensitivity. The authors are to be commended for designing and executing a robust study that has implications for glucoregulatory and cardiovascular pathophysiology in diabetes. The present findings add to prior cognate demonstration that ACTH infusion reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia (4). Together, these reports link ACTH to the mechanisms involved in the metabolic, neuroendocrine, and baroreflex components of HAAF. Although the authors focus on ACTH as the possible effector of their finding of decreased baroreflex sensitivity, it should be noted that circulating cortisol and aldosterone levels increased 2- to 3-fold following the ACTH infusion. (Activation of glucocorticoid or mineralocorticoid receptors can induce HAAF, and aldosterone decreases baroreflex sensitivity.) Plasma ACTH levels also would have risen substantially (possibly, >10-fold above the physiological range) during the infusion. The increased plasma ACTH could reach the hypothalamus via the median eminence (which is not hindered by the blood-brain barrier) and suppress CRH secretion. As CRH is known to stimulate autonomic outflow, leading to increased heart rate, cardiac output, catecholamine levels, and other sympathetic responses, its inhibition by ACTH infusion could have chronotropic and hemodynamic effects (6). Thus, the reported effect of ACTH on baroreflex sensitivity could have resulted from elevated cortisol, elevated aldosterone, elevated ACTH, or suppressed CRH levels. Clearly, the collective data from the present study and previous pertinent observations do implicate the hypothalamic-pituitary-adrenal axis in the mechanism underlying components of HAAF. However, the hierarchy among axis entities—CRH, ACTH, cortisol, and aldosterone—in the mediation of the HAAF syndrome remains to be elucidated. Despite the lack of a clear unifying mechanism, HAAF is a clinically important syndrome that increases the risk of iatrogenic hypoglycemia and sequelae (including arrhythmias and death) in people with diabetes. The study by Leung et al (this issue) observed a decrease in baroreflex sensitivity from ~18 mmHg/ms to 15 mmHg/ms following infusion of stress levels of ACTH, with a fairly wide inter-individual variation, such that ~50% of subjects experienced >20% decrease in sensitivity. That magnitude of baroreflex blunting could have untoward cardiac and hemodynamic consequences in patients with diabetes who have developed HAAF or are exposed to hypoglycemic stress. Fortunately, the hormonal, metabolic and behavioral manifestations of HAAF are reversible with scrupulous avoidance of iatrogenic hypoglycemia (1,2,4,7). Indeed, current standards of care recommendations stress the avoidance of hypoglycemia to mitigate the devastating consequences of severe hypoglycemia in patients with a history of hypoglycemia unawareness or HAAF. It is hoped, although yet to be shown, that the baroreflex component of HAAF also is reversible, using a similar approach. Financial Support: S.D.-J. is supported, in part, by grants R01 DK067269, DK62203, and DK 48411 from the National Institutes of Health. Disclosure Summary: The author has no conflicts of interest to disclose regarding the content of this article. Data Availability: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
No takes yet. Share an insight, caveat, or question.
Sam Dagogo‐Jack (2020) conducted an editorial in Hypoglycemia-Associated Autonomic Failure. ACTH 1-24 (cosyntropin) infusion vs. Placebo was evaluated on Baroreflex sensitivity. ACTH 1-24 infusion decreased baroreflex sensitivity from ~18 mmHg/ms to 15 mmHg/ms in healthy subjects, implicating the hypothalamic-pituitary-adrenal axis in hypoglycemia-associated autonomic failure.
Synapse has enriched 10 related papers. Consider them for comparative context: